

21 Na+
5' HO
Gf Gm Uf Um Af Am Cf Am Cf Cf Af Um Uf Um Af Cm Uf Um Cf Am Af
L96 3'
A-116858
A-116861
GmAm Cm Cf Am Af Um Uf Gm Uf Gm GmUm Af Am Af Um Gf Am Af Gm Uf Um
3' HO
OH 5'
22 Na+
Af, Cf, Gf, Uf = 2'-F ribonucleosides
Am, Cm, Gm, Um = 2'-OMe ribonucleosides
L96 =
AcHN
HO
OH
O
N
H

FIG. 1

Molecular formula and molecular mass

	Fitusiran (Duplex)	A-116858 (Sense strand)	A-116861 (Antisense strand)
Molecular formula sodium salt	$C_{520}H_{636}F_{21}N_{175}Na_{43}O_{309}P_{43}S_6$	$C_{285}H_{369}F_{12}N_{85}Na_{21}O_{164}P_{21}S_2$	$C_{235}H_{267}F_9N_{90}Na_{22}O_{145}P_{22}S_4$
Molecular formula free acid	$C_{520}H_{679}F_{21}N_{175}O_{309}P_{43}S_6$	$C_{285}H_{390}F_{12}N_{85}O_{164}P_{21}S_2$	$C_{235}H_{289}F_9N_{90}O_{145}P_{22}S_4$
Molecular weight sodium salt	17,193 Da	9,035 Da	8,159 Da
Molecular weight free acid	16,248 Da	8,573 Da	7,675 Da

FIG. 1 Continued



17 patients randomized
6 patients received fitusiran 50 mg
11 patients received fitusiran 80 mg
0 patients discontinued or withdrawn
0 patients discontinued or withdrawn
6 patients included in PD/PK Analysis Set
6 patients included in Safety Analysis Set
11 patients included in PD/PK Analysis Set
11 patients included in Safety Analysis Set
6 patients completed study
11 patients completed study

FIG. 2



D-Dimer (ug/mL)
7
6
5
4
3
2
1
0
-60
-30
0
30
60
90
120
Days since first dose

FIG. 3A



D-Dimer (ug/mL)
7
6
5
4
3
2
1
0
-60
-30
0
30
60
90
120
Days since first dose

FIG. 3B



Mean [+/- SEM] Antithrombin Activity Relative to Baseline
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
30
60
90
120
Days Since First Dose
Dose Group ▲MDI 50 mg (N=6) ◇MDI 80 mg (N=11)

FIG. 4A



Mean [+/- SEM] Plasma Thrombin Generation Peak Height (mmol/L)
100
90
80
70
60
50
40
30
20
10
0.0
0
30
60
90
120
Days Since First Dose
Dose Group ▲MDI 50 mg (N=6) ◇MDI 80 mg (N=11)

FIG. 4B



Thrombin Generation Peak Height (nmol/L)
240
220
200
180
160
140
120
100
80
60
40
20
0
Healthy Volunteers (N=4)
AT Lowering <25% (N=14)
AT Lowering 25<50% (N=11)
AT Lowering 50<75% (N=15)
AT Lowering >=75% (N=17)

FIG. 5